(NASDAQ:SRPT) plunged to $19.91, down $16.27, or almost 45%, on word of a second death by acute liver failure (ALF) with Elevidys (delandistrogene moxeparvovec), the approved gene therapy for patients ...

Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential.

Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio.

Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with ...

ROCKVILLE, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...

ONAPGO™ (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year 2025 financial guidance. ... Supernus will host a conference call and webcast today, May 6, ...

Supernus Pharmaceuticals, Inc. reported strong financial results for the first quarter of 2025, with Qelbree® net sales rising 44% to $64.7 million and GOCOVRI® sales increasing 16% to $30.7 ...

Supernus Pharmaceuticals, Inc. First quarter 2025 net sales of Qelbree ® increased 44% to $64.7 million, compared to the same period in 2024.. First quarter 2025 net sales of GOCOVRI ® increased 16% ...

ONAPGO™ (apomorphine hydrochloride) ... Supernus will host a conference call and webcast today, May 6, 2025, at 4:30 p.m. Eastern Time to discuss these results.

ROCKVILLE, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...